California State Teachers Retirement System Has $1.97 Million Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

California State Teachers Retirement System grew its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 82.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 36,735 shares of the company's stock after purchasing an additional 16,575 shares during the period. California State Teachers Retirement System owned about 0.06% of Janux Therapeutics worth $1,967,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of JANX. RA Capital Management L.P. lifted its stake in Janux Therapeutics by 13.1% in the 4th quarter. RA Capital Management L.P. now owns 10,365,652 shares of the company's stock worth $554,977,000 after acquiring an additional 1,200,000 shares in the last quarter. FMR LLC grew its stake in Janux Therapeutics by 10.8% in the fourth quarter. FMR LLC now owns 8,669,941 shares of the company's stock valued at $464,189,000 after purchasing an additional 845,266 shares in the last quarter. Janus Henderson Group PLC increased its position in Janux Therapeutics by 41.2% in the 4th quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company's stock worth $190,617,000 after purchasing an additional 1,038,996 shares during the last quarter. Paradigm Biocapital Advisors LP increased its position in Janux Therapeutics by 46.5% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company's stock worth $188,246,000 after purchasing an additional 1,115,412 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its position in Janux Therapeutics by 47.6% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company's stock worth $163,926,000 after purchasing an additional 986,750 shares during the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

JANX has been the topic of several research reports. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 target price on shares of Janux Therapeutics in a research report on Monday, March 3rd. Scotiabank lowered their price objective on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a report on Friday, February 28th. Finally, Wedbush reissued an "outperform" rating and set a $76.00 price objective (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $95.25.

Insider Buying and Selling

In related news, insider Andrew Hollman Meyer sold 3,333 shares of the firm's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $32.03, for a total transaction of $106,755.99. Following the completion of the sale, the insider now directly owns 82,139 shares of the company's stock, valued at $2,630,912.17. This trade represents a 3.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 8.10% of the stock is owned by corporate insiders.

Janux Therapeutics Stock Down 3.0%

Shares of JANX stock traded down $0.78 during mid-day trading on Wednesday, reaching $25.46. The stock had a trading volume of 605,445 shares, compared to its average volume of 868,811. The firm's 50 day simple moving average is $26.97 and its 200 day simple moving average is $37.36. Janux Therapeutics, Inc. has a one year low of $22.48 and a one year high of $71.71. The firm has a market cap of $1.51 billion, a PE ratio of -21.76 and a beta of 2.96.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.